JP2018505681A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505681A5
JP2018505681A5 JP2017541675A JP2017541675A JP2018505681A5 JP 2018505681 A5 JP2018505681 A5 JP 2018505681A5 JP 2017541675 A JP2017541675 A JP 2017541675A JP 2017541675 A JP2017541675 A JP 2017541675A JP 2018505681 A5 JP2018505681 A5 JP 2018505681A5
Authority
JP
Japan
Prior art keywords
binding site
bispecific antibody
antigen binding
antibody
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541675A
Other languages
English (en)
Japanese (ja)
Other versions
JP6970017B2 (ja
JP2018505681A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/017141 external-priority patent/WO2016130539A2/en
Publication of JP2018505681A publication Critical patent/JP2018505681A/ja
Publication of JP2018505681A5 publication Critical patent/JP2018505681A5/ja
Application granted granted Critical
Publication of JP6970017B2 publication Critical patent/JP6970017B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541675A 2015-02-09 2016-02-09 ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用 Active JP6970017B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113988P 2015-02-09 2015-02-09
US62/113,988 2015-02-09
PCT/US2016/017141 WO2016130539A2 (en) 2015-02-09 2016-02-09 Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505681A JP2018505681A (ja) 2018-03-01
JP2018505681A5 true JP2018505681A5 (enExample) 2020-06-11
JP6970017B2 JP6970017B2 (ja) 2021-11-24

Family

ID=56614713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541675A Active JP6970017B2 (ja) 2015-02-09 2016-02-09 ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用

Country Status (9)

Country Link
US (2) US10988534B2 (enExample)
EP (1) EP3256164B1 (enExample)
JP (1) JP6970017B2 (enExample)
CN (1) CN107847584B (enExample)
AU (1) AU2016219534B2 (enExample)
CA (1) CA2976074A1 (enExample)
ES (1) ES2789573T3 (enExample)
IL (1) IL253871B (enExample)
WO (1) WO2016130539A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107124884B (zh) 2014-07-25 2022-11-01 纪念斯隆-凯特林癌症中心 双特异性her2和cd3结合分子
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
US10988534B2 (en) * 2015-02-09 2021-04-27 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
WO2019010299A1 (en) 2017-07-06 2019-01-10 Memorial Sloan Kettering Cancer Center DOTA-HAPTENE COMPOSITIONS FOR RADIOIMMUNOTHERAPY PRECIBLED BY A BISPECIFIC ANTIGEN ANTI-DOTA / ANTI-TUMOR ANTIBODY
CN111372590A (zh) * 2017-09-23 2020-07-03 纪念斯隆-凯特林癌症中心 A33抗体组合物及在放射免疫疗法中使用其的方法
CN112088169A (zh) * 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
US20220031871A1 (en) * 2018-04-16 2022-02-03 Hoffmann-La Roche Inc. Antibodies for chelated radionuclides and clearing agents
MY207044A (en) * 2018-04-16 2025-01-27 Hoffmann La Roche Antibodies for chelated radionuclides
WO2020219715A1 (en) * 2019-04-23 2020-10-29 The Trustees Of The University Of Pennsylvania A dota-binding chimeric antigen receptor for cellular therapy
KR20230024326A (ko) 2020-06-04 2023-02-20 와이-맙스 테라퓨틱스 인코포레이티드 암의 치료를 위한 항-b7h3 항체
JP2023530675A (ja) 2020-06-17 2023-07-19 ワイ-マブス セラピューティクス, インコーポレイテッド ヒト疾患の治療のためのcd38抗体
CA3184225A1 (en) * 2020-06-29 2022-01-06 Steven Larson C825 expressing immune cells and diagnostic uses thereof
US20230346988A1 (en) * 2020-06-29 2023-11-02 Memorial Sloan Kettering Cancer Center Systems for in vivo monitoring of immune cells in patients undergoing cellular immunotherapy
WO2022005991A1 (en) * 2020-06-29 2022-01-06 Memorial Sloan Kettering Cancer Center Platform for assessing in vivo and in vitro hapten-capture in a cell bound system
US20230365636A1 (en) 2020-11-16 2023-11-16 Technische Universität München Bioorthogonal reporter gene system
US20240026037A1 (en) * 2020-11-18 2024-01-25 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US6190640B1 (en) * 1985-04-19 2001-02-20 Ludwig Institute For Cancer Research Method for treating neoplasia using humanized antibodies which bind to antigen A33
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993025788A1 (en) 1992-06-09 1993-12-23 Hoppe Ag Latch and lockset system
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5413823A (en) 1994-02-02 1995-05-09 Shippers Paper Products Company Collapsible and expandable roll riser
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5886793A (en) 1995-04-04 1999-03-23 Oki Data Corporation Facsimile machine adapted to reduce risk of data loss
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
WO1998000433A1 (en) 1996-07-03 1998-01-08 President And Fellows Of Harvard College Template-directed interference footprinting of protein-adenine contacts
SI0956865T2 (sl) 1996-08-12 2011-04-29 Mitsubishi Pharma Corp Zdravila, ki obsegajo inhibitor Rho-kinaze
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955186A (en) 1996-10-15 1999-09-21 Kennametal Inc. Coated cutting insert with A C porosity substrate having non-stratified surface binder enrichment
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
ATE427966T1 (de) 1997-02-11 2009-04-15 Immunomedics Inc Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6795722B2 (en) 2001-06-18 2004-09-21 Neotech Products, Inc. Electrode sensor package and application to the skin of a newborn or infant
US20030026764A1 (en) * 2001-07-31 2003-02-06 Immunomedics, Inc. Polymeric delivery systems
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
CA2531118C (en) * 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
ES2589769T3 (es) * 2009-02-27 2016-11-16 Massachusetts Institute Of Technology Proteínas modificadas con alta afinidad por quelatos de DOTA
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CN112812184A (zh) * 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
WO2012133782A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
US10487155B2 (en) * 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10167341B2 (en) * 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
US10988534B2 (en) * 2015-02-09 2021-04-27 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
US11963965B2 (en) 2019-12-26 2024-04-23 National Jewish Health Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction

Similar Documents

Publication Publication Date Title
JP2018505681A5 (enExample)
TWI821474B (zh) Cd3抗體及其藥物用途
JP2019535670A5 (enExample)
JP2018504105A5 (enExample)
JP2019527553A5 (enExample)
CN112969476B (zh) 多特异性蛋白分子
JP2020534830A5 (enExample)
JP2020503870A5 (enExample)
JP2017114866A5 (enExample)
JP2020525032A5 (enExample)
JP2015163068A5 (enExample)
JP2012523848A5 (enExample)
JP2013506428A5 (enExample)
JP2018516554A5 (enExample)
JP2018527919A5 (enExample)
JP2012501670A5 (enExample)
JP2018516853A5 (enExample)
JP2013538057A5 (enExample)
RU2020120613A (ru) Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
RU2016100892A (ru) Антитела против tweakr и их применение
JP2016516400A5 (enExample)
JP2011207882A5 (enExample)
RU2018128414A (ru) Новое psma-связывающее антитело и его применения
JP2021500916A5 (enExample)
JP2018530331A5 (enExample)